As of 2026-05-26, the Intrinsic Value of Hikma Pharmaceuticals PLC (HIK.L) is 1,984.95 GBP. This HIK.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1,459.00 GBP, the upside of Hikma Pharmaceuticals PLC is 36.00%.
The range of the Intrinsic Value is 1,617.71 - 2,540.54 GBP
Based on its market price of 1,459.00 GBP and our intrinsic valuation, Hikma Pharmaceuticals PLC (HIK.L) is undervalued by 36.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 1,617.71 - 2,540.54 | 1,984.95 | 36.0% |
| DCF (Growth 10y) | 1,780.60 - 2,699.66 | 2,148.68 | 47.3% |
| DCF (EBITDA 5y) | 2,233.95 - 3,369.97 | 2,942.07 | 101.6% |
| DCF (EBITDA 10y) | 2,382.21 - 3,641.26 | 3,100.00 | 112.5% |
| Fair Value | 2,327.86 - 2,327.86 | 2,327.86 | 59.55% |
| P/E | 3,361.81 - 4,586.43 | 3,638.27 | 149.4% |
| EV/EBITDA | 2,191.42 - 3,785.21 | 3,249.90 | 122.7% |
| EPV | 1,555.80 - 2,148.41 | 1,852.11 | 26.9% |
| DDM - Stable | 1,063.79 - 1,987.79 | 1,525.79 | 4.6% |
| DDM - Multi | 1,275.58 - 1,849.67 | 1,509.51 | 3.5% |
| Market Cap (mil) | 3,052.65 |
| Beta | 0.69 |
| Outstanding shares (mil) | 2.09 |
| Enterprise Value (mil) | 4,085.27 |
| Market risk premium | 5.98% |
| Cost of Equity | 10.58% |
| Cost of Debt | 5.94% |
| WACC | 8.93% |